Press releaseGlobe Newswire
Spero Therapeutics
SPRO · NASDAQ
$1.22−$0.0005 (−0.04%)TodayMarket closed ·
Prev close $1.22
Latest news
- Press releaseGlobe Newswire
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
- News
Spero Therapeutics Enters License Agreement With Innovent Biologics For Exclusive Rights To Develop, Research, Manufacture, And Commercialize SP001 Globally Ex-China
- Press releaseGlobe Newswire
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
- Press releasePRNewswire
Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
- Press releaseGlobe Newswire
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
- Press releaseGlobe Newswire
Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors
- Press releaseGlobe Newswire
Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
- NewsAvi Kapoor
Why Smith & Wesson Brands Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- Press releaseBusiness Wire
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
- NewsVandana Singh
GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs
- Press releaseGlobe Newswire
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
- Press releaseBusiness Wire
Compass Pathways Elects Kathleen Tregoning to Board of Directors
- News
Earnings Scheduled For May 13, 2026
- News
Spero Therapeutics Q4 EPS $0.53 Beats $(0.40) Estimate, Sales $41.297M Up From $15.044M YoY
- News
Earnings Scheduled For March 26, 2026
- News
Earnings Scheduled For November 13, 2025
- News
Insights Ahead: Spero Therapeutics's Quarterly Earnings
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- News
Earnings Scheduled For August 12, 2025
- News
Earnings Outlook For Spero Therapeutics
- NewsAvi Kapoor
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
- News
Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- NewsAvi Kapoor
Crude Oil Gains 2%; Macy's Lowers Earnings Forecast
- NewsVandana Singh
Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?
- NewsAvi Kapoor
US Stocks Gain; Abercrombie & Fitch Posts Upbeat Earnings
- News
Market-Moving News for May 28th
- News
The Analyst Verdict: Spero Therapeutics In The Eyes Of 4 Experts
- News
What 4 Analyst Ratings Have To Say About Spero Therapeutics
- News
Spero Therapeutics's Earnings Outlook
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- NewsAvi Kapoor
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.